29 April 2025
Watkin Jones plc (‘Watkin Jones’ or the ‘Company’) H1-2025 Trading Update The Group provides the following trading update for the half year ended 31…
Jet2 plc (“the Group” or “the Company”) Trading Update Full year results in line with expectations and £250m Share Buyback announced Jet2 plc, the…
AstraZeneca results: Q1 2025 Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition Revenue and EPS summary Q1…
24 April 2025
Three-month sales 2025: Delivering broad-based growth, executing on strategy Sales performance summary Total Group Zone Americas Zone AOA Zone Europe Nestlé Health Science Nespresso…
Unilever Trading Statement – First Quarter 2025 Resilient performance, full year outlook reconfirmed (unaudited) First Quarter 2025 USG Turnover Vs 2024 Unilever 3.0% €14.8bn (0.9)%…
23 April 2025
B.P. Marsh & Partners Plc (“B.P. Marsh” or the “Company”) New Investment – iO Finance Partners Topco Limited (“iO Partners”) B.P. Marsh (AIM: BPM), the…
(the “Company” or Group”) AGM Trading Update Trading and FY outlook in line with expectations with the Group well placed to make further progress…
22 April 2025
Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic breast…